NCT02636010 - Pembrolizumab (MK-3475) in MM Patients With Residual Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

February 20, 2020

Conditions

Multiple Myeloma

Interventions

DRUG

Pembrolizumab

Trial Locations (11)

Hoapital Clinico Universitario Salamanca, Salamanca

Hospital Germans Trias i Pujol, Badalona

Hospital Clinic, Barcelona

Hospital 12 de octubre, Madrid

Hospital Ramón y Cajal, Madrid

Hospital General Morales Messeguer, Murcia

Hospital General Universitario Morales Messeguer, Murcia

Clinica Universitaria de Navarra, Pamplona

Hospital Universitario Virgen del Rocio, Seville

Hospital Universitario Doctor Peset, Valencia

Hospital Clinico de Zaragoza, Zaragoza